{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042659","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.775172+00:00","generated_at":"2026-05-24T10:27:58.011104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Erasca reports FY2024 net loss $161.7M; cash $440.5M; pipeline on track for 2025 IND filings","bullets":["Net loss for FY2024 $161.7M ($0.69/sh) vs $125.0M ($0.83/sh) in 2023.","Cash, equivalents & marketable securities $440.5M at Dec 31, 2024, up from $322.0M; runway extended to H2 2027.","R&D expenses $115.4M (excl. $22.5M in-process R&D) vs $103.8M; G&A $41.7M vs $37.7M.","IND filings expected mid-Q2 2025 for pan-RAS glue ERAS-0015 and Q2 2025 for pan-KRAS inhibitor ERAS-4001.","Phase 3 SEACRAFT-2 (naporafenib+trametinib) Stage 1 random data H2 2025; FDA FTD in NRASm melanoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042659","json":"https://secwatch.observer/filing/0000950170-25-042659.json","markdown":"https://secwatch.observer/filing/0000950170-25-042659.md","text":"https://secwatch.observer/filing/0000950170-25-042659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/0000950170-25-042659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/eras-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:27:58.011104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}